↓ Skip to main content

Kinase Inhibitors

Overview of attention for book
Cover of 'Kinase Inhibitors'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Targeting Cancer with Small-Molecular-Weight Kinase Inhibitors.
  3. Altmetric Badge
    Chapter 2 Small-Molecule Protein and Lipid Kinase Inhibitors in Inflammation and Specific Models for Their Evaluation
  4. Altmetric Badge
    Chapter 3 Measuring the Activity of Leucine-Rich Repeat Kinase 2: A Kinase Involved in Parkinson’s Disease
  5. Altmetric Badge
    Chapter 4 Measuring PI3K Lipid Kinase Activity
  6. Altmetric Badge
    Chapter 5 A Fluorescence Polarization Assay for the Discovery of Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1
  7. Altmetric Badge
    Chapter 6 Assessment of Hepatotoxicity Potential of Drug Candidate Molecules Including Kinase Inhibitors by Hepatocyte Imaging Assay Technology and Bile Flux Imaging Assay Technology
  8. Altmetric Badge
    Chapter 7 Kinase Inhibitors
  9. Altmetric Badge
    Chapter 8 Chemoproteomic characterization of protein kinase inhibitors using immobilized ATP.
  10. Altmetric Badge
    Chapter 9 Proteome-Wide Identification of Staurosporine-Binding Kinases Using Capture Compound Mass Spectrometry
  11. Altmetric Badge
    Chapter 10 Affinity Purification of Proteins Binding to Kinase Inhibitors Immobilized on Self-Assembling Monolayers
  12. Altmetric Badge
    Chapter 11 Kinase Inhibitor Profiling Using Chemoproteomics
  13. Altmetric Badge
    Chapter 12 Covalent cross-linking of kinases with their corresponding peptide substrates.
  14. Altmetric Badge
    Chapter 13 Receptor Tyrosine Kinase Inhibitor Profiling Using Bead-Based Multiplex Sandwich Immunoassays
  15. Altmetric Badge
    Chapter 14 Monitoring Phosphoproteomic Response to Targeted Kinase Inhibitors Using Reverse-Phase Protein Microarrays
  16. Altmetric Badge
    Chapter 15 Measuring Phosphorylation-Specific Changes in Response to Kinase Inhibitors in Mammalian Cells Using Quantitative Proteomics
  17. Altmetric Badge
    Chapter 16 Investigation of Acquired Resistance to EGFR-Targeted Therapies in Lung Cancer Using cDNA Microarrays
Attention for Chapter 1: Targeting Cancer with Small-Molecular-Weight Kinase Inhibitors.
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (83rd percentile)
  • High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

twitter
1 X user
patent
2 patents

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
80 Mendeley
citeulike
4 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Targeting Cancer with Small-Molecular-Weight Kinase Inhibitors.
Chapter number 1
Book title
Kinase Inhibitors
Published in
Methods in molecular biology, January 2012
DOI 10.1007/978-1-61779-337-0_1
Pubmed ID
Book ISBNs
978-1-61779-336-3, 978-1-61779-337-0
Authors

Doriano Fabbro, Sandra W. Cowan-Jacob, Henrik Möbitz, Georg Martiny-Baron, Fabbro, Doriano, Cowan-Jacob, Sandra W., Möbitz, Henrik, Martiny-Baron, Georg

Abstract

Protein and lipid kinases fulfill essential roles in many signaling pathways that regulate normal cell functions. Deregulation of these kinase activities lead to a variety of pathologies ranging from cancer to inflammatory diseases, diabetes, infectious diseases, cardiovascular disorders, cell growth and survival. 518 protein kinases and about 20 lipid-modifying kinases are encoded by the human genome, and a much larger proportion of additional kinases are present in parasite, bacterial, fungal, and viral genomes that are susceptible to exploitation as drug targets. Since many human diseases result from overactivation of protein and lipid kinases due to mutations and/or overexpression, this enzyme class represents an important target for the pharmaceutical industry. Approximately one third of all protein targets under investigation in the pharmaceutical industry are protein or lipid kinases.The kinase inhibitors that have been launched, thus far, are mainly in oncology indications and are directed against a handful of protein and lipid kinases. With one exception, all of these registered kinase inhibitors are directed toward the ATP-site and display different selectivities, potencies, and pharmacokinetic properties. At present, about 150 kinase-targeted drugs are in clinical development and many more in various stages of preclinical development. Kinase inhibitor drugs that are in clinical trials target all stages of signal transduction from the receptor protein tyrosine kinases that initiate intracellular signaling, through second-messenger-dependent lipid and protein kinases, and protein kinases that regulate the cell cycle.This review provides an insight into protein and lipid kinase drug discovery with respect to achievements, binding modes of inhibitors, and novel avenues for the generation of second-generation kinase inhibitors to treat cancers.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 3%
Germany 1 1%
Bulgaria 1 1%
Netherlands 1 1%
Brazil 1 1%
Canada 1 1%
Unknown 73 91%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 17 21%
Researcher 12 15%
Student > Bachelor 10 13%
Professor 9 11%
Student > Doctoral Student 6 8%
Other 14 18%
Unknown 12 15%
Readers by discipline Count As %
Chemistry 20 25%
Biochemistry, Genetics and Molecular Biology 16 20%
Agricultural and Biological Sciences 11 14%
Medicine and Dentistry 7 9%
Pharmacology, Toxicology and Pharmaceutical Science 6 8%
Other 8 10%
Unknown 12 15%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 November 2021.
All research outputs
#4,481,876
of 22,653,392 outputs
Outputs from Methods in molecular biology
#1,278
of 13,011 outputs
Outputs of similar age
#38,725
of 244,011 outputs
Outputs of similar age from Methods in molecular biology
#77
of 473 outputs
Altmetric has tracked 22,653,392 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,011 research outputs from this source. They receive a mean Attention Score of 3.3. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 244,011 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 473 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.